Summary
Regeneron Pharmaceuticals, Inc. (REGN) reported strong financial performance in 2015, driven primarily by significant growth in its lead product, EYLEA. EYLEA demonstrated robust sales growth of 54% year-over-year, solidifying its position as the market-leading anti-VEGF therapy in the U.S. The company also achieved key regulatory milestones, including U.S. and European approval for Praluent (alirocumab) for LDL cholesterol reduction, marking a significant entry into the cardiovascular market. The company's pipeline advanced with positive Phase 3 data for sarilumab in rheumatoid arthritis and progressed dupilumab in atopic dermatitis and asthma, indicating strong future growth potential. Regeneron's commitment to innovation is further evidenced by its advanced genomics initiatives and strategic collaborations. Financially, the company saw substantial increases in both total revenues and net income, reflecting its successful commercialization efforts and ongoing pipeline development. Investors should note the continued reliance on EYLEA for a substantial portion of revenue, alongside the significant potential of Praluent and its robust pipeline. The company's strong financial results and strategic partnerships position it well for future growth, though ongoing regulatory and competitive landscapes remain key factors to monitor.
Financial Highlights
47 data points| Revenue | $4.10B |
| Cost of Revenue | $241.70M |
| Gross Profit | $3.86B |
| R&D Expenses | $1.62B |
| SG&A Expenses | $838.53M |
| Operating Expenses | $2.85B |
| Operating Income | $1.25B |
| Interest Expense | $14.24M |
| Net Income | $636.06M |
| EPS (Basic) | $6.17 |
| EPS (Diluted) | $5.52 |
| Shares Outstanding (Basic) | 103.06M |
| Shares Outstanding (Diluted) | 115.23M |
Key Highlights
- 1EYLEA® (aflibercept) Injection delivered 54% net sales growth in 2015, becoming the market-leading branded anti-VEGF therapy in the U.S.
- 2Praluent® (alirocumab) Injection received regulatory approval in the U.S. and Europe for LDL cholesterol reduction and has been launched in key markets.
- 3Positive Phase 3 data for sarilumab in rheumatoid arthritis was reported, with a regulatory application submitted to the FDA.
- 4Significant progress was made with dupilumab, including positive Phase 2b data in asthma and completion of Phase 3 enrollment for atopic dermatitis.
- 5Two antibody candidates, REGN2222 for RSV prevention and fasinumab for osteoarthritis pain, advanced to Phase 3 studies.
- 6Regeneron expanded its R&D collaborations with Mitsubishi Tanabe Pharma and Sanofi (immuno-oncology).
- 7The company's genomics initiative advanced significantly, with the capacity to sequence 100,000 exomes annually.